Latest Middle East News

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

Orica Limited reported a 7.7% increase in revenue to $3.94 billion for the half year ended March 2025, but posted a net loss of $89 million due to significant impairment and restructuring charges. Excluding these items, net profit rose 40% to $250.8 million, with the board declaring a higher interim dividend.

Unibail-Rodamco-Westfield and Cenomi Centers have entered a decade-long exclusive partnership to bring the Westfield brand to Saudi Arabia’s premier shopping centres, aiming to reshape retail experiences across the Kingdom’s largest cities.

Hazer Group has entered a binding six-year strategic alliance with global engineering leader KBR to exclusively market and license its methane pyrolysis technology, targeting the ammonia and methanol sectors. This partnership aims to accelerate commercialisation, expand global reach, and materially de-risk Hazer’s business plan.

Gale Pacific has sharply downgraded its full-year EBITDA guidance due to tariff-driven demand softness in the US, while its Australia, New Zealand, and developing markets hold steady.

Vmoto Limited reported a 16% decline in total unit sales for 1Q25, offset by a strong cash position and strategic investments in e-mobility solutions and production capacity.

Imricor Medical Systems has initiated its first MRI-guided atrial flutter ablation procedures at Semmelweis University in Budapest, marking a significant expansion of its real-time MRI technology in Europe.

Harvest Technology Group reported a 19% improvement in normalized EBITDA for Q3 FY25 alongside a $1.6 million capital raise, reinforcing its strategic plan to achieve profitability by FY27.

Eden Innovations reports robust growth in EdenCrete®Pz7 sales, driven by expanded orders from Holcim Ecuador and the USA, alongside strategic US property sales aimed at debt reduction and operational efficiency.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

X2M Connect reports a challenging quarter with a 64% revenue drop due to exiting low-margin hardware sales but boosts gross margin and expands its footprint with new contracts in the Middle East and South Korea alongside launching an AI platform for renewables.

EOS is midway through a strategic turnaround, divesting non-core assets and strengthening its balance sheet while advancing cutting-edge counter-drone, high energy laser weapons, and space control technologies amid robust global demand.